In Vivo Bone-Targeting of Bis(phosphonate)-Conjugated Double Helical RNA Monitored by Positron Emission Tomography.

@article{Jadhav2016InVB,
  title={In Vivo Bone-Targeting of Bis(phosphonate)-Conjugated Double Helical RNA Monitored by Positron Emission Tomography.},
  author={Satish Jadhav and Meeri K{\"a}kel{\"a} and Matthieu Bourgery and Kiira Rimpil{\"a} and Heidi Liljenb{\"a}ck and Riikka Siitonen and Jussi M{\"a}kil{\"a} and Tiina K Laitala-Leinonen and P{\"a}ivi Poij{\"a}rvi-Virta and Harri L{\"o}nnberg and Anne Roivainen and Pasi Virta},
  journal={Molecular pharmaceutics},
  year={2016},
  volume={13 7},
  pages={2588-95}
}
A bis(phosphonate) conjugate of 2'-O-methyl oligoribonucleotide (microRNA-21) was synthesized and used as a bone-targeting carrier in the systemic delivery of a (68)Ga-1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA)-chelated 2'-O-methyl oligoribonucleotide (anti-microRNA-21). The whole-body biodistribution of the double helical RNA was monitored by positron emission tomography (PET), which verified the expected bis(phosphonate)-induced bone accumulation in healthy rats.